News Image

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

Provided By GlobeNewswire

Last update: Jun 11, 2025

All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response (PERR); first patient to reach 1-year follow-up continues in drug-free Definition of Remission in SLE (DORIS)

Read more at globenewswire.com

FATE THERAPEUTICS INC

NASDAQ:FATE (8/15/2025, 8:18:16 PM)

After market: 1.14 +0.05 (+4.59%)

1.09

+0.02 (+1.87%)



Find more stocks in the Stock Screener

FATE Latest News and Analysis

Follow ChartMill for more